Ampio Pharmaceuticals Inc.
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $7.69 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Ampio Pharmaceuticals Inc. had its IPO on under the ticker symbol AMPED.
The company operates in the Healthcare sector and Biotechnology industry. Ampio Pharmaceuticals Inc. has a staff strength of 9 employees.
Shares of Ampio Pharmaceuticals Inc. opened at $0.26 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $0.26 - $0.29, and closed at $0.27.
This is a -0.48% slip from the previous day's closing price.
A total volume of 143,839 shares were traded at the close of the day’s session.
In the last one week, shares of Ampio Pharmaceuticals Inc. have slipped by -13.32%.
Ampio Pharmaceuticals Inc.'s Key Ratios
Ampio Pharmaceuticals Inc. has a market cap of $7.69 million, indicating a price to book ratio of 0.4707 and a price to sales ratio of 0.
In the last 12-months Ampio Pharmaceuticals Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-25781000. The EBITDA ratio measures Ampio Pharmaceuticals Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ampio Pharmaceuticals Inc.’s operating margin was 0% while its return on assets stood at -81.42% with a return of equity of -130.71%.
In Q3, Ampio Pharmaceuticals Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Ampio Pharmaceuticals Inc.’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ampio Pharmaceuticals Inc.’s profitability.
Ampio Pharmaceuticals Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.3776. Its price to sales ratio in the trailing 12-months stood at 0.
Ampio Pharmaceuticals Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $18.84 million
- Total Liabilities
- $3.92 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Ampio Pharmaceuticals Inc. ended 2023 with $18.84 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.84 million while shareholder equity stood at $13.85 million.
Ampio Pharmaceuticals Inc. ended 2023 with $0 in deferred long-term liabilities, $3.92 million in other current liabilities, 2000.00 in common stock, $-231719000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $16.95 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Ampio Pharmaceuticals Inc.’s total current assets stands at $18.32 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $218000.00 and inventory worth $0.00.
In 2023, Ampio Pharmaceuticals Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Ampio Pharmaceuticals Inc. paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Ampio Pharmaceuticals Inc. stock is currently trading at $0.27 per share. It touched a 52-week high of $9.705 and a 52-week low of $9.705. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.31 and 200-day moving average was $1.75 The short ratio stood at 1.13 indicating a short percent outstanding of 0%.
Around 750.6% of the company’s stock are held by insiders while 1317.6% are held by institutions.
Frequently Asked Questions About Ampio Pharmaceuticals Inc.
Similar Industry Stocks (Biotechnology)
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.